All filters
Slidesets
Antibody Therapies for COVID-19 - Daniel Kuritzkes, MD
Presented at:
COVID-19 Online Educational Program 2020
Slidesets
Long-Term Effects of COVID-19 - Cristina Mussini, MD
Presented at:
COVID-19 Online Educational Program 2020
Slidesets
COVID-19 in Pregnancy and Possible Mother-to-Child SARS-CoV-2 Transmission - Lynne Mofenson, MD
Presented at:
COVID-19 Online Educational Program 2020
Slidesets
Sivaporn Gatechompol | Selected Treatment Highlights - CROI 2020 - Regional Relevance
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Jean-Michel Molina | Implementation of PrEP - Efficacy and Resistance Considerations
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Iskandar Azwa | Implementation of PrEP - Social Aspects and STI Risk Compensation
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Sasisopin Kiertiburanakul | Opening Lecture: HIV Drug Resistance in Asia
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Stephane Wen-Wei Ku | PrEP Implementation in Real-Life (Case-Based Presentation)
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Opass Putcharoen | HIV Subtypes - Virologic and Resistance Implications
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Mark Nelson | Clinical Case Presentation
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
Kiat Ruxrungtham | Two Versus Three Drugs - Relevance for the Asian Settings
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Slidesets
David Back | HIV Gender & Ethnicity - Implications for Toxicity and Altered Pharmacology
Presented at:
Asia-Pacific HIV Clinical Forum 2020
Abstracts
Clinical case presentation: A preliminary profile of common co-morbidities and risk practices in a sample of HIV/HCV co-infected patients in Puerto Rico
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Implementation science for HIV prevention using an eHealth program for Spanish-speaking sexual minorities groups in Puerto Rico
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
High prevalence of hepatitis B virus infection among chronic kidney disease patients
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Time to treatment disfavors patients living with HIV/HCV co-infection
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Prevalence of alcohol and substance use in a sample of patients living with HIV/HCV co-infection who are in routine clinical care receiving antiretroviral therapy
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Efficacy and safety of sofosbuvir/velpatasvir for the treatment of patients with chronic hepatitis C genotype 1-6 infection: Integrated analysis of eight Phase 3 clinical trials
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Heterogeneity in priorities for continuing education training among clinicians providing (or not!) HIV and HCV clinical services
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Automated electrochemiluminescence assay could be used for screening hepatitis B and C markers in dried blood spot samples?
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
96 Week efficacy and safety of B/F/TAF in treatment-naïve adults and adults ≥ 50 years
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Tenofovir alafenamide vs tenofovir DF in women: Pooled analysis of 7 clinical trials
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019